Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.

The event that initiates the extrinsic pathway of blood coagulation is the association of coagulation factor VIIa (VIIa) with its cell-bound receptor, tissue factor (TF), exposed to blood circulation following tissue injury and/or vascular damage. The natural inhibitor of the TF.VIIa complex is the first Kunitz domain of tissue factor pathway inhibitor (TFPI-K1). The structure of TF. VIIa reversibly inhibited with a potent (Ki=0.4 nM) bovine pancreatic trypsin inhibitor (BPTI) mutant (5L15), a homolog of TFPI-K1, has been determined at 2.1 A resolution. When bound to TF, the four domain VIIa molecule assumes an extended conformation with its light chain wrapping around the framework of the two domain TF cofactor. The 5L15 inhibitor associates with the active site of VIIa similar to trypsin-bound BPTI, but makes several unique interactions near the perimeter of the site that are not observed in the latter. Most of the interactions are polar and involve mutated positions of 5L15. Of the eight rationally engineered mutations distinguishing 5L15 from BPTI, seven are involved in productive interactions stabilizing the enzyme-inhibitor association with four contributing contacts unique to the VIIa.5L15 complex. Two additional unique interactions are due to distinguishing residues in the VIIa sequence: a salt bridge between Arg20 of 5L15 and Asp60 of an insertion loop of VIIa, and a hydrogen bond between Tyr34O of the inhibitor and Lys192NZ of the enzyme. These interactions were used further to model binding of TFPI-K1 to VIIa and TFPI-K2 to factor Xa, the principal activation product of TF.VIIa. The structure of the ternary protein complex identifies the determinants important for binding within and near the active site of VIIa, and provides cogent information for addressing the manner in which substrates of VIIa are bound and hydrolyzed in blood coagulation. It should also provide guidance in structure-aided drug design for the discovery of potent and selective small molecule VIIa inhibitors.

[1]  Y. Nemerson.  Tissue factor and hemostasis. , 1988, Blood.

[2]  J. Miletich,et al.  Human tissue factor: cDNA sequence and chromosome localization of the gene. , 1987, Biochemistry.

[3]  M. Ultsch,et al.  The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution. , 1996, Journal of molecular biology.

[4]  T. Edgington,et al.  Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade , 1987, Cell.

[5]  J. Trewhella,et al.  The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study. , 1996, Biochemistry.

[6]  R. Huber,et al.  Structure of human des(1-45) factor Xa at 2.2 A resolution. , 1993, Journal of molecular biology.

[7]  M. Ultsch,et al.  Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. , 1994, Biochemistry.

[8]  W. Novotny,et al.  Regulation of coagulation by a multivalent Kunitz-type inhibitor. , 1990, Biochemistry.

[9]  W. Ruf,et al.  Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H Brandstetter,et al.  X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[12]  A. Tulinsky,et al.  Structure of bovine prothrombin fragment 1 refined at 2.25 A resolution. , 1991, Journal of molecular biology.

[13]  O. Olsen,et al.  Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. , 1996, European journal of biochemistry.

[14]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[15]  F. Castellino,et al.  The influence of metal ions in the activation of bovine factor IX by the coagulant protein of Russell's viper venom. , 1978, Archives of biochemistry and biophysics.

[16]  D. Bharadwaj,et al.  Factor VII Central , 1996, The Journal of Biological Chemistry.

[17]  A. Tulinsky,et al.  The molecular environment of the Na+ binding site of thrombin. , 1997, Biophysical chemistry.

[18]  A. Tulinsky,et al.  The calcium ion and membrane binding structure of the Gla domain of calcium-prothrombin fragment 1 , 1992 .

[19]  P. Handford,et al.  The structure of a Ca2+-binding epidermal growth factor-like domain: Its role in protein-protein interactions , 1995, Cell.

[20]  W. Ruf,et al.  Ca2+ Binding to the First Epidermal Growth Factor Module of Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function* , 1997, The Journal of Biological Chemistry.

[21]  W A Hendrickson,et al.  Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. , 1992, Science.

[22]  J Deisenhofer,et al.  Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. , 1974, Journal of molecular biology.

[23]  S. Bajaj,et al.  Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Ullner,et al.  How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X. , 1994, The Journal of biological chemistry.

[25]  G. Broze,et al.  Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.

[26]  A. Tulinsky,et al.  Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. , 1998, Biochemistry.

[27]  R. Huber,et al.  The thrombin E192Q–BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin , 1997, The EMBO journal.

[28]  F. Castellino,et al.  Kinetic studies of the role of monovalent cations in the amidolytic activity of activated bovine plasma protein C. , 1982, Biochemistry.

[29]  C. Orthner,et al.  Evidence that human alpha-thrombin is a monovalent cation-activated enzyme. , 1980, Archives of biochemistry and biophysics.

[30]  Axel T. Brunger,et al.  X-PLOR Version 3.1: A System for X-ray Crystallography and NMR , 1992 .

[31]  E. Di Cera,et al.  Thrombin is a Na(+)-activated enzyme. , 1992, Biochemistry.

[32]  R. Wesselschmidt,et al.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. , 1992, Blood.

[33]  L. Petersen,et al.  Two different Ca2+ ion binding sites in factor VIIa and in des(1–38) factor VIIa , 1992, FEBS letters.

[34]  I. Campbell,et al.  1H NMR assignment and secondary structure of the cell adhesion type III module of fibronectin. , 1992, Biochemistry.

[35]  R. Fletterick,et al.  Crystal structures of rat anionic trypsin complexed with the protein inhibitors APPI and BPTI. , 1993, Journal of molecular biology.

[36]  D. Stuart,et al.  Crystal structure of the extracellular region of human tissue factor , 1994, Nature.

[37]  K. Williams,et al.  Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Wilson,et al.  Crystallization and preliminary crystallographic data for a ternary complex between tissue factor, factor VIIa and a BPTI-derived inhibitor , 1996 .

[39]  David W. Banner,et al.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.

[40]  T S Edgington,et al.  The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. , 1998, Journal of molecular biology.

[41]  W. Bode,et al.  The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. , 1975, Journal of molecular biology.

[42]  W. Ruf,et al.  Tissue Factor: molecular recognition and cofactor function , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  S. Rapaport,et al.  Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J H Matthews,et al.  Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin. , 1999, Journal of medicinal chemistry.

[45]  D. Turk,et al.  The refined 1.9‐Å X‐ray crystal structure of d‐Phe‐Pro‐Arg chloromethylketone‐inhibited human α‐thrombin: Structure analysis, overall structure, electrostatic properties, detailed active‐site geometry, and structure‐function relationships , 1992, Protein science : a publication of the Protein Society.

[46]  W. Hendrickson.  Stereochemically restrained refinement of macromolecular structures. , 1985, Methods in enzymology.

[47]  P. Hogg,et al.  Effects of Ca2+ binding on the protease module of factor Xa and its interaction with factor Va. Evidence for two Gla-independent Ca(2+)-binding sites in factor Xa. , 1993, Journal of Biological Chemistry.

[48]  F. Castellino,et al.  The binding of calcium to bovine factor VII. , 1980, Archives of biochemistry and biophysics.

[49]  R. Huber,et al.  The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. , 1997, Journal of molecular biology.

[50]  S Foundling,et al.  The 2.8 A crystal structure of Gla‐domainless activated protein C. , 1996, The EMBO journal.

[51]  W. Bode,et al.  The refined crystal structure of bovine β-trypsin at 1·8 Å resolution , 1975 .

[52]  J. Vermylen,et al.  Characterisation of a Novel Series of Aprotinin-Derived Anticoagulants , 1995, Thrombosis and Haemostasis.

[53]  J H Matthews,et al.  Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site. , 1996, Biophysical journal.

[54]  J. Birktoft,et al.  High Affinity Ca2+-binding Site in the Serine Protease Domain of Human Factor VIIa and Its Role in Tissue Factor Binding and Development of Catalytic Activity (*) , 1995, The Journal of Biological Chemistry.

[55]  W. Ruf,et al.  Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor. , 1995, Biochemistry.

[56]  W. Kisiel,et al.  Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. , 1991, The Journal of biological chemistry.

[57]  Y. Nemerson,et al.  Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor. , 1977, The Journal of biological chemistry.

[58]  G. Broze,et al.  The effect of leukocyte elastase on tissue factor pathway inhibitor. , 1992, Blood.

[59]  S. Rapaport,et al.  Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. , 1989, Blood.

[60]  A. D. de Vos,et al.  The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. , 1994, Biochemistry.

[61]  Z. Zhang,et al.  Crystal growth. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. Orthner,et al.  The effect of metal ions on the amidolytic acitivity of human factor Xa (activated Stuart-Prower factor). , 1978, Archives of biochemistry and biophysics.

[63]  B. Osterud,et al.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Schullek,et al.  Tissue Factor residue Asp44 regulates catalytic function of the bound proteinase Factor VIIa. , 1996, The Biochemical journal.

[65]  J. Clardy,et al.  Comparison of the structures of the cyclotheonamide a complexes of human α‐thrombin and bovine β‐trypsin , 1996, Protein science : a publication of the Protein Society.

[66]  R. Huber,et al.  Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. Crystal structure determination and stereochemistry of the contact region. , 1973, Journal of molecular biology.

[67]  D. Banner,et al.  Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex , 1995, Proteins.

[68]  M. Dennis,et al.  Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. , 1994, The Journal of biological chemistry.

[69]  O. Nordfang,et al.  Effect of Leukocyte Proteinases on Tissue Factor Pathway Inhibitor , 1992, Thrombosis and Haemostasis.

[70]  I. Lasters,et al.  Strategies in the Design of Inhibitors of Serine Proteases of the Coagulation Cascade - Factor Xa , 1995, European Journal of Medicinal Chemistry.

[71]  P. Weber,et al.  Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs. , 1995, Biochemistry.